Breast Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardBreast CancerBreast CancerSCE Medical Oncology

Metastatic triple-negative breast cancer has progressed after an anthracycline-taxane regimen for early disease, then carboplatin-gemcitabine and capecitabine for advanced disease. HER2 is IHC 0 and germline BRCA testing is negative. Which next treatment has the matching NICE indication?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Sacituzumab govitecan

Explanation lettering: C = shown as B · E = shown as C · B = shown as D · D = shown as E

D is correct. Sacituzumab govitecan is recommended after at least two prior systemic therapies, with at least one given for advanced triple-negative disease; this patient has exceeded that threshold. Trastuzumab deruxtecan requires a qualifying HER2-low or HER2-positive pathway rather than IHC 0 in this scenario. Olaparib and talazoparib require a germline BRCA alteration. Eribulin is an active later-line cytotoxic option, but NICE places sacituzumab in this specifically eligible population before routine eribulin use. Neutropenia and diarrhoea risk still require proactive monitoring.

Reference: NICE TA819 sacituzumab govitecan recommendations: https://www.nice.org.uk/guidance/ta819/chapter/1-Recommendations